Registration deadline: 21/9/2022

  • Date: 22nd September 2022 (Thursday)
  • Time: 19:00 – 20:30 (GMT+8)
  • Webinar: Zoom platform

CME accreditations Approved:

  • Hong Kong College of Physicians (1.0)
  • Hong Kong College of Paediatricians (1.0)
  • Hong Kong College of Radiologists (1.5)
  • The Hong Kong College of Pathologists (1.0)

Organized by 

  • Hong Kong Society of Haematology

Supported by 

  • MEDcentra

Sponsored by

  • Servier


19:00 – 19:05

  • Opening remarks – Dr. Law Man-Fai

19:05 -19:20

Treatment of adult ALL in Hong Kong

            Dr. Law Man-Fai

19:20 -19:40

Management of childhood Acute Lymphoblastic Leukaemia in Hong Kong

Acute lymphoblastic leukaemia (ALL) is the commonest childhood malignancy with about 30 new cases per million populations below age of 15 years. The treatment result of childhood ALL has improved remarkably in the past few decade, the 5-year overall survival is now approaching 90%.

Paediatric ALL treatment has been standardised in Hong Kong since early 90s, and all the hospitals adopted the uniform treatment protocol. Subsequently the Hong Kong Group participated in a number of international and national clinical research studies, the latest one is CCCG 2020 ALL study.

The treatment strategy aims at improving treatment efficacy but reducing early and late toxicities. Cranial irradiation as prophylactic CNS directed treatment has been eliminated in the recent 3 studies.

There are also important changes in chemotherapy agents including the more frequent use of dexamethasone for better CNS protection and anti-leukaemic effect, pegylated asparaginase as the standard first line treatment and high dose methotrexate. With the multi-agent chemotherapy protocols, treatment side effects and complications are common but manageable. The treatment related mortality is below 5%.

However adolescents develop more significant complications and need close monitoring and treatment adjustment, the outcome of adolescents is now approaching the younger children. The paediatric inspired chemotherapy protocols have also been studied in some adult ALL studies with promising results.

            Prof. Li Chi-Kong

19:40 -20:10

An Australia perspective: AYA & Adult ALL management & Pegaspargase RWE

Adolescent and Young Adult patients represent a unique group in the management of Acute Lymphoblastic Leukaemia, where with the use of paediatric inspired regimens incorporating the use of asparaginase superior outcomes can be attained as compared to when adult regimens are utilised, though their outcome remains inferior to that of children.

AYA patients bring unique aspects to the management of asparaginase with a divergent toxicity profile from that seen in paediatric patients. We will discuss these aspect to management and the Australian experience with the use of paediatric inspired regimens in AYA patients.

            Dr. Shaun Fleming

20:10 – 20:25

  • Q&A Session

20:25 – 20:30

  • Concluding remarks – Dr. Law Man-Fai